A copy of the application is sufficient evidence to a supplier
What the document says“``(4) if the person sends a copy of the application described in paragraph (1) to a manufacturer or distributor of the substance, receipt of the copy by the manufacturer or distributor shall constitute sufficient evidence that the person is authorized to receive the substance.''.”
Where the person sends a copy of the application to a manufacturer or distributor of the substance, receipt of that copy counts as sufficient evidence that the person is authorized to receive it.
What the document actually says“``(4) if the person sends a copy of the application described in paragraph (1) to a manufacturer or distributor of the substance, receipt of the copy by the manufacturer or distributor shall constitute sufficient evidence that the person is authorized to receive the substance.''.”
The researcher can send a copy of the papers to a supplier. Getting that copy is proof enough for the supplier. It shows the researcher may take the drug.
The papers are not yet approved at this stage. The rule says the copy counts as proof. The supplier can then hand over the drug.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.